Recent Company News

• 07:55 AM ET Jun 16, 2026
  

  FDA grants orphan drug designation to GLPG3667 for dermatomyositis (€24.56, -0.52)

• 04:02 PM ET Jun 09, 2026
  

  Lakefront Biotherapeutics announces initiation of €50M stock repurchase program (€24.24, 0.00)

• 04:02 PM ET Jun 08, 2026
  

  Lakefront Biotherapeutics appoints Eric Hedrick as Chief Medical Officer (€24.36, 0.00)

• 04:20 PM ET Jun 04, 2026
  

  Gilead Sciences, Lakefront complete acquisition of Ouro Medicines ($129.18, 0.00)

• 10:01 AM ET May 19, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (145 total)

• 04:25 AM ET May 18, 2026
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (84 total)

• 10:29 AM ET May 07, 2026
  

  Transcript Intelligence: Galapagos Q1 Earnings Guidance

• 10:29 AM ET May 07, 2026
  

  Transcript Intelligence: Galapagos Q1 Earnings Themes

• 10:29 AM ET May 07, 2026
  

  Transcript Intelligence: Galapagos Q1 Earnings Q&A

• 04:05 PM ET May 06, 2026
  

  Galapagos reports Q1 EPS €0.21 vs FactSet (€0.82) [3 est, (€1.10)-(0.51)] (€24.62, 0.00)